about
Possession of human leucocyte antigen DQ6 alleles and the rate of CD4 T-cell decline in human immunodeficiency virus-1 infectionHigh levels of type 2 cytokine-producing cells in chronic fatigue syndromeMore tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimersPeptide length determines the outcome of TCR/peptide-MHCI engagementStructural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes.Autoantibodies to autonomic nerves associated with cardiac and peripheral autonomic neuropathyPrevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysisPeripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell deathA model for harmonizing flow cytometry in clinical trials.Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognitionNaturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppressionComparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells.Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity.Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers.Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes.Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline.Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetesHeterogeneity in the Locomotory Behavior of Human Monocyte Subsets over Human Vascular Endothelium In Vitro.Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes.Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramersAntibody stabilization of peptide-MHC multimers reveals functional T cells bearing extremely low-affinity TCRsImmunological dysfunction, vaccination and Gulf War illnessLong-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial.A systematic review and critical evaluation of the immunology of chronic fatigue syndrome.Variation of Peripheral Blood Mononuclear Cell RNA Quality in Archived Samples.How Representative Are Research Tissue Biobanks of the Local Populations? Experience of the Infectious Diseases Biobank at King's College, London, UKEnteroviruses and type 1 diabetes.A single autoimmune T cell receptor recognizes more than a million different peptides.Autoreactive T cells in human type 1 diabetes.Antigen targets of type 1 diabetes autoimmunityResident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation.β-cell-specific CD8 T cell phenotype in type 1 diabetes reflects chronic autoantigen exposure.Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function.Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill β-cells.Can we vaccinate against Type 1 diabetes?Human β-cell killing by autoreactive preproinsulin-specific CD8 T cells is predominantly granule-mediated with the potency dependent upon T-cell receptor avidity.CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope.Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity.Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture.
P50
Q24682861-F9CDEDB7-7C94-44DB-A7D8-2809C8A393B0Q24684394-7BAE7406-4490-4F0D-96CF-7FEFCEC47F59Q26864749-BAA6724C-04F0-440F-8EA6-67720CF06816Q27675544-9A305D8F-66F3-4730-AC4A-CE36F79CA932Q27676742-E817DF25-523F-4D59-87F9-62322C2B7E91Q28263600-4CF76739-BD4A-46AD-8E9B-A6E054F40876Q28303840-1157AE1F-C15C-4039-8329-CEB9C3337623Q28582005-A113FCEB-21CF-4277-A5C2-1948A9A61CFAQ30425924-DE402CD3-5F06-4869-807F-35D609C0D5FEQ33635226-A76D2606-A3DC-4CD2-ABA1-B3473CBCC390Q33869793-111A6A00-6FAA-464B-8052-C17CEB86E18AQ33871399-24AB28D3-08D0-49F1-99D1-F10A525E99C6Q33916508-6082D502-8738-40C1-8E4A-8BEE96B0B629Q33930268-704F0882-F67D-42C0-AA5F-C3FC57D63440Q34065354-A929247B-423C-4321-8B64-F729FB0A0371Q34082782-FECC6A09-84B9-428A-959C-9C5BFD2C5C0DQ34227866-5FDCB371-307B-4001-884C-4E2C147CA0C0Q34393377-5FF163F8-F35E-4653-85A4-AC67309E7A9DQ34481213-8D6776E9-D189-478F-9366-A9CD085C1D7DQ34553677-1D781EDF-92B5-4EEB-9791-709BD0D084A8Q34641211-01CDE0B0-2D09-48FB-8D19-405A6C4D17C4Q34756907-15DC368F-6BEB-413A-A1BF-FDCB382F6FBFQ35038290-41F7E291-2E80-4053-AB09-C2352005DA8BQ35060161-315ADF4A-FC3F-45D8-885B-C3C02184D076Q35204532-FA330857-1312-458B-9D82-E1BDF233A893Q35227413-834ED4C3-4CD6-4A70-846C-DFFE2EC676C0Q35227422-024F5242-6BB4-47CC-BECA-C038C21F2CF2Q35597416-4D454763-8C1A-4EA3-AED3-B8363DFFF4DAQ35668865-F4C21D62-CBA5-4F4C-B366-F78DA6C22FDFQ35725784-226657E8-21C8-4BE6-A635-584BA965B923Q35852999-FF02826F-0512-4694-86E7-CC98791C6CC0Q35946105-E8883E2C-3C90-4369-9851-A82E7E4AF08DQ36019335-44804DC0-C025-4BB9-A511-9EDAB78C5532Q36043724-BBAAC84F-1B2A-4C00-9C14-047F1395B303Q36047607-8CE8B864-588B-4F63-B628-80418F79D0C7Q36296386-2C434C76-DDC0-4002-A40F-E5B4ED35AB08Q36477211-A322890C-7D6E-44AA-B867-4EB425F4145CQ36890836-543DAEEF-44A9-4822-A4AB-C91E5BFEF124Q36951745-1BDD0EDF-1E0D-41AE-8B54-7A3FE61E737FQ37023012-C234D6EF-2D26-4A58-B470-EB51EA6E0A87
P50
description
researcher ORCID ID = 0000-0003-3328-3513
@en
name
Mark Peakman
@ast
Mark Peakman
@en
Mark Peakman
@es
Mark Peakman
@nl
type
label
Mark Peakman
@ast
Mark Peakman
@en
Mark Peakman
@es
Mark Peakman
@nl
prefLabel
Mark Peakman
@ast
Mark Peakman
@en
Mark Peakman
@es
Mark Peakman
@nl
P21
P31
P496
0000-0003-3328-3513